期刊
MOLECULAR PSYCHIATRY
卷 16, 期 6, 页码 620-625出版社
SPRINGERNATURE
DOI: 10.1038/mp.2011.38
关键词
CYP450; CYP3A43; genetics; olanzapine; pharmacogenetics; pharmacokinetics
资金
- Division of Intramural Research, National Institute of Mental Health, National Institutes of Health
- National Institute of Mental Health [N01 MH900001, MH074027]
- Eli Lilly and Company
The antipsychotic drug, olanzapine, one of the most widely used drugs in clinical medicine, has a high rate of discontinuation due to inefficacy and/or adverse effects. We identified a single nucleotide polymorphism in the drug metabolizing enzyme, cytochrome P450 3A43 (CYP3A43; rs472660), that highly significantly predicted olanzapine clearance in the Clinical Antipsychotic Trials of Intervention Effectiveness trial (P = 5.9e(-7)). Moreover, at standard antipsychotic doses, 50% of individuals with the high clearance genotype (AA) have trough blood levels below the therapeutic range. Interestingly, a much higher proportion of African Americans carry the A allele compared with Caucasians (allele frequency 67 vs 14%). After accounting for CYP3A43 genotype, race is no longer a significant predictor of olanzapine clearance. Olanzapine clearance was associated with measures of clinical response. Patients with greater clearance had higher symptom ratings and were more likely to discontinue treatment due to an inadequate response. Our data identify a genetic mechanism for variation in olanzapine response and demonstrate that blood level monitoring of olanzapine treatment is advisable. Molecular Psychiatry (2011) 16, 620-625; doi:10.1038/mp.2011.38; published online 26 April 2011
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据